The Economics of the Obesity Drug Industry: Competition, Policy and Profitability

According to the World Health Organisation (WHO), approximately 2.5 billion people, aged 18 or over were overweight in 2022, including 890 million living with obesity. Economic developments, urbanization and shifts in diet and physical activity have contributed to a global public health crisis with over 1 billion people currently diagnosed with obesity. While the WHO recommends preventing and managing obesity through interventions such as improved nutrition and increased physical activity, long term weight maintenance has proven difficult for many people. Pharmaceutical innovation has therefore emerged as a potential solution for patients seeking medical treatment for obesity.

In recent years, obesity treatment has shifted from behavioural and physical management to pharmaceutical intervention. Healthcare companies such as Eli Lilly, a medicine company aiming to improve lives and communities, and Novo Nordisk, focusing on creating long term health. Novo Nordisk’s mission is to treat and prevent obesity through their GLP- 1 therapy, aiming to reduce appetite and support patients’ long-term health. They believe that only 11% of people attempting to lose weight have maintained it for more than 1 year, with the global obesity rate tripling since 1975. On the other hand, Eli Lilly prescribes Zepound, an injection that may help adults with obesity to lose body weight and keep it off.

However, this industry is rapidly evolving from a breakthrough into a competitive industry to gain higher market share. Novo Nordisk released their data on its obesity drug CagriSema, achieving a 23% average weight loss in an 84-week trial, compared to 25.5% for Eli Lilly’s tirzepatide. Although the difference appears marginal, financial markets reacted sharply: Novo’s shares fell around 16% in a single day, while Eli Lilly’s rose. This divergence shows how even small differences in a clinical trial can alter expectations of profitability and market share.

Furthermore, competition from others within the industry is fierce, including Hims & Hers, where Novo is suing them for selling a knock off version. Hims and Hers planned to sell their version at $49 a month whilst Novo Nordisk’s is at $149 for the lowest dose. On top of competition, economic pressures are rising. The Trump Administration aims to improve affordability and accessibility for patients in the healthcare industry. 

Novo recently forecasted that sales could decline by 5-13% in 2026 due to pricing pressures in the United States. In contrast, Eli Lilly offset these price reductions through rapid volume growth, reporting a triple digit increase in global sales of its weight loss medicines in recent quarters. This shift suggests that the obesity drug market is entering a new phase. Growing competition, government intervention and potential patent expiries are reshaping the industry and changing the market capitalisation between Novo Nordisk and Eli Lilly.

Beyond financial performance, ethical considerations remain central. Obesity disproportionately affects lower income countries due to malnutrition: their high fat, sugar and salt diets. Yet these therapies can cost hundreds of dollars per month without insurance coverage. Governments seek to balance affordability with incentives for pharmaceutical innovation. The tensions between shareholder returns and patient access underscores a broader question: can medical breakthroughs remain commercially sustainable while being socially equitable?

Ultimately, the weight loss drug industry shows how modern pharmaceutical markets operate within science, finance and public policy. What began as a medical breakthrough has evolved into a global competitive and economic background. As innovation continues, long term success will depend on the ability to balance profitability with public health responsibility.